Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

  1. Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
    Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
    Year: 2025
  2. Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
    Year: 2025
  3. Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
    Year: 2024
    Citations: 4
  4. Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
    Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
    Year: 2024
    Citations: 6
  5. Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
    Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
    Year: 2024
    Citations: 2
  6. Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
    Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
    Year: 2024
  7. Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
    Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
    Year: 2024
  8. Title: The role of NCAPH in cancer treatment
    Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
    Year: 2024
  9. Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
    Year: 2024
    Citations: 2
  10. Title: Natural products with anti-tumorigenesis potential targeting macrophage
    Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
    Year: 2024

 

Rashna Mirza | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Ms. Rashna Mirza | Pharmaceutical Science | Best Researcher Award

PhD scholar of Quaid-i-Azam University, Pakistan.

Rashna Mirza is a distinguished researcher currently pursuing a PhD at Quaid-i-Azam University, Islamabad, focusing on advanced drug delivery systems, including brain-targeted transfersomes and optimized nano-transfersomes. A Gold Medalist in Pharm D from People’s University of Medical and Health Sciences for Women, she has demonstrated exceptional academic and research prowess. Her professional experience includes roles in quality assurance, pharmaceutical research, and laboratory supervision, showcasing her expertise in drug formulation and optimization. Rashna’s commitment to the field is reflected in her impactful publications and active participation in conferences. Her strengths lie in cutting-edge research, scientific communication, and organizational skills, though expanding her research impact and gaining leadership experience could further enhance her profile. Rashna’s background and achievements make her a strong candidate for the Research for Best Researcher Award.

Profile

Education

Rashna Mirza’s educational background reflects her strong commitment to the field of pharmaceutics. She is currently pursuing a PhD at Quaid-i-Azam University, Islamabad, with research focused on advanced drug delivery systems, including brain targeting of Cefepime-loaded transfersomes and optimization of nano-transfersomes for transdermal delivery. Prior to her PhD, Rashna completed her M.Phil at the same institution, where she continued to build on her expertise in pharmaceutics. She earned her Pharm D from People’s University of Medical and Health Sciences for Women, where she graduated as a Gold Medalist, underscoring her exceptional academic performance. Rashna’s foundational education includes an FSC Pre-Medical from Government Girls Degree College, Islamabad, and matriculation from Foundation Public School, Karachi. This robust educational background has equipped her with a deep understanding of pharmaceutical sciences and a solid foundation for her research career.

Professional Experience

Rashna Mirza has a diverse professional background that underscores her expertise in pharmaceutics and drug development. Currently pursuing her PhD at Quaid-i-Azam University, she is engaged in pioneering research on brain-targeted drug delivery systems and transdermal gels. Her experience includes working as a Lab Demonstrator at Quaid-i-Azam University, where she managed laboratory work, supervised experiments, and facilitated instructional activities. She also served as a Quality Assurance Inspector at Herbiotics, where she conducted inspections, quality audits, and process monitoring. Additionally, Rashna worked as a Retail Pharmacist at Punjab Pharmacy, handling inventory management, patient counseling, and medication therapy management. Her academic journey is marked by her gold medal achievement in Pharm D from People’s University of Medical and Health Sciences for Women. Her professional roles reflect her strong organizational, supervisory, and research skills, contributing significantly to her field.

Research Interest

Rashna Mirza’s research interests center on the development and optimization of novel drug delivery systems to enhance therapeutic outcomes. Her current PhD research focuses on innovative approaches such as brain-targeting of Cefepime-loaded transfersomes and the formulation of nano-transfersomes-based chitosan gels for transdermal delivery. This work aims to improve drug efficacy and patient compliance through advanced delivery mechanisms. Rashna is also interested in the formulation and optimization of thermosensitive in situ gels, exploring their potential for controlled and targeted drug release. Her research integrates both in vitro and in vivo studies to address challenges in pharmaceutical science, emphasizing the importance of precise drug delivery for effective treatment. Rashna’s work is characterized by a commitment to advancing pharmaceutics through rigorous experimentation and collaboration, contributing valuable insights to the field and aiming to bridge gaps in current drug delivery technologies.

Research Skills

Rashna Mirza exhibits a strong suite of research skills that underscore her capabilities in advancing the field of pharmaceutics. Her expertise in drug formulation and optimization is evident through her current PhD research, which involves innovative drug delivery systems such as brain-targeting transfersomes and nano-transfersomes. Rashna’s proficiency in statistical design and optimization further enhances her ability to develop and refine novel drug delivery methods. Her hands-on laboratory skills are complemented by her experience in quality assurance and process monitoring, ensuring meticulous evaluation and control of research processes. Additionally, Rashna’s solid background in scientific communication and report writing enables her to effectively present and disseminate research findings. Her involvement in interdisciplinary collaboration and active participation in conferences reflects her commitment to integrating diverse perspectives and advancing scientific knowledge. Overall, Rashna’s research skills demonstrate a well-rounded and impactful approach to pharmaceutics and drug development.

Award and Recognition

Rashna Mirza, a distinguished researcher and Gold Medalist in Pharm D, has garnered significant recognition for her contributions to the field of pharmaceutics. Her innovative research on drug delivery systems, including brain-targeting transfersomes and nano-transfersome optimization, has been widely acknowledged within the scientific community. Rashna’s work is prominently featured in impactful publications, reflecting her dedication to advancing drug formulation and optimization. Her role as a Lab Demonstrator and Quality Assurance Inspector highlights her exceptional skills in scientific communication, process improvement, and interdisciplinary collaboration. Additionally, Rashna’s participation in notable conferences and her involvement in quality audits further underscore her commitment to excellence in pharmaceutical research. These achievements collectively affirm her as a leading figure in her field, earning her well-deserved recognition and positioning her as a promising candidate for prestigious awards in pharmaceutics and drug development.

Conclusion

Rashna Mirza’s strong background in pharmaceutics, demonstrated research capabilities, and commitment to advancing drug delivery systems position her as a suitable candidate for the Research for Best Researcher Award. Her strengths in innovative research, academic excellence, and effective communication support her candidacy, while opportunities for broader impact and leadership development could further enhance her profile.

Publication Top Notes

  • Brain targeting of cefepime loaded transfersomes based thermosensitive in situ gel via intranasal delivery: In vitro and in vivo studies
    • Authors: R. Mirza, A.U. Khan, K.U. Shah, F. Alasmari, Z. Hafeez
    • Year: 2024
    • Citations: 1
  • Statistical design and optimization of nano-transfersomes based chitosan gel for transdermal delivery of cefepime
    • Authors: R. Mirza, K.U. Shah, A.U. Khan, Z. Hafeez, S.U. Haq
    • Year: 2024

 

 

GHADEER SUAIFAN | Pharmaceutical Sciences | Best Researcher Award

Posted on by ScienceFather

Prof GHADEER SUAIFAN | Pharmaceutical Sciences | Best Researcher Award

Research Scholar, The University of Jordan, Jordan

Ghadeer A. Suaifan was born in December 1973 and is a Jordanian national. She is fluent in both Arabic and English. Ghadeer holds a PhD and an MPhil in Medicinal Chemistry and Instrumental Analysis from the University of Bath, UK, and a BSc (Honours) in Pharmacy from Petra University, Jordan. She currently serves as a Professor of Medicinal Chemistry and Pharmaceutical Instrumental Analysis at the Faculty of Pharmacy, The University of Jordan. Her research interests span medicinal chemistry, nanotechnology, and public health, with significant contributions in optimizing antidiabetic candidates, cancer treatments, and developing advanced analytical techniques. Ghadeer has published extensively and holds several patents.

Profile

Education🎓

From 2001 to 2004, Ghadeer A. Suaifan pursued a PhD in Medicinal Chemistry and Instrumental Analysis at the Department of Pharmacy and Pharmacology, University of Bath, UK. Prior to this, she completed an MPhil in Medicinal Chemistry and Instrumental Analysis at the same institution from 2000 to 2001. Ghadeer began her academic journey with a BSc (Honours) in Pharmacy from the College of Pharmacy, Petra University, Amman, Jordan, which she completed between 1991 and 1996. Her foundational education was acquired at Al-Room Al-Catholic School in Zarka, Jordan, where she earned her General Secondary Education Certificate from 1988 to 1991.

Experience 🏢

Prof. Ghadeer Suaifan is a distinguished Professor of Medicinal Chemistry and Pharmaceutical Instrumental Analysis at the Faculty of Pharmacy, The University of Jordan, where she has been serving since September 2016. In this role, she leads advanced research and teaching, significantly contributing to the academic and research excellence of the institution. Prior to this, she held the position of Associate Professor from September 2012 to September 2016, during which she focused on enhancing the curriculum and advancing research initiatives in medicinal chemistry and pharmaceutical sciences. From 2005 to 2012, Prof. Suaifan worked as an Assistant Professor at the same faculty, delivering undergraduate and postgraduate courses in pharmaceutical sciences and engaging in significant research activities. Additionally, she served as an Assistant Professor at the Faculty of Pharmacy, Philadelphia University, Amman, Jordan, from 2004 to 2005, where she contributed to the development of pharmaceutical education and research. Prof. Suaifan’s extensive experience and dedication have made her a vital asset to the field of pharmaceutical sciences in Jordan.

Research Interests 🔬

Ghadeer’s research encompasses Medicinal Chemistry and Instrumental Analysis, focusing on optimizing new antidiabetic candidates, elucidating molecular structures, and developing advanced prodrug systems for prostate cancer. Her work extends to Nanotechnology, including biological particle detection, miniaturized instrumentation, and medical diagnostics. She also investigates Public Research, evaluating antibiotic use behaviors and the prevalence of Complementary and Alternative Medicine in Jordan.

Special Awards 🏆

Professor Ghadeer Suaifan has been recognized for her outstanding contributions to research and development. She received the prestigious Ibtikar Award from Mewiin, Kuwait, in 2020. Her dedication to scientific research was further acknowledged with the Samia Mango Award from the Hamdi Mango Center for Scientific Research in Amman, Jordan, in 2018. In 2015, she was honored with the Excellent Oral Presenter Award at the International Conference on Pharmaceutical Sciences (ICPS) held in Dubai. Professor Suaifan’s academic achievements were consistently recognized during her time at the Faculty of Pharmacy, Petra University, where she received University Awards for Best Achievement from 1991 to 1996. In addition to her accolades, she has been a Registered Pharmacist with the Jordanian Pharmacists Association in Amman since January 1996, showcasing her longstanding commitment to the pharmaceutical profession and her continuous contributions to the field.

Publications Top Notes 📚

  1. Magnetic beads-based nanozyme for portable colorimetric biosensing of Helicobacter pylori
    • Authors: Suaifan, G.A.R.Y., Shehadeh, M.B., Darwish, R.M., Alaridah, N., Zourob, M.
    • Year: 2024
    • Journal: Biosensors and Bioelectronics: X, Volume 20, Article 100517
  2. Rapid Colorimetric Quantitative Portable Platform for Detection of Brucella melitensis Based on a Fluorescence Resonance Energy Transfer Assay and Nanomagnetic Particles
    • Authors: Alhogail, S., Chinnappan, R., Suaifan, G.A., Jürgen, P., Zourob, M.M.
    • Year: 2024
    • Journal: ACS Omega, Volume 9, Issue 19, Pages 20997–21005
  3. A cross-sectional study on adult lifestyle habits during the COVID-19 pandemic
    • Authors: Suaifan, G.A.R.Y., Abu-Odeh, A.M., Shehadeh, M.B., Jbara, W.A., Nassar, R.I.
    • Year: 2024
    • Journal: PLoS ONE, Volume 19, Issue 5, Article e0299668
  4. Synthesis, urease inhibitory and anticancer evaluation of glucosamine-sulfonylurea conjugates
    • Authors: Suaifan, G.A.R.Y., Shehadeh, M., Tahboub, D., Gaurav, A., Khan, M.
    • Year: 2024
    • Journal: Medicinal Chemistry Research, Volume 33, Issue 4, Pages 663–676
  5. Glucosamine substituted sulfonylureas: IRS-PI3K-PKC-AKT-GLUT4 insulin signalling pathway intriguing agent
    • Authors: Suaifan, G.A.R.Y., Alkhawaja, B., Shehadeh, M.B., Hor Kuan, C., Okechukwu, P.N.
    • Year: 2024
    • Journal: RSC Medicinal Chemistry, Volume 15, Issue 2, Pages 695–703
  6. Development of Rapid Aptamer-Based Screening Assay for the Detection of Covid-19 Variants
    • Authors: Aloraij, Y.M., Suaifan, G.A.R.Y., Shibl, A., Al-Kattan, K., Zourob, M.M.
    • Year: 2023
    • Journal: ACS Omega, Volume 8, Issue 36, Pages 32877–32883
  7. Medicinal plants of Jordan: Scoping review
    • Authors: Abu-Odeh, A., Fino, L., Al-Absi, G., Shehadeh, M., Suaifan, G.
    • Year: 2023
    • Journal: Heliyon, Volume 9, Issue 6, Article e17081
  8. Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy
    • Authors: Suaifan, G.A.R.Y., Abdel Rahman, D.M.A., Abu-Odeh, A.M., Shehadeh, M.B., Darwish, R.M.
    • Year: 2023
    • Journal: PLoS ONE, Volume 18, Issue 3, Article e0282705
  9. Knowledge, practice and attitude associated with SARS-CoV-2 Delta Variant among adults in Jordan
    • Authors: Suaifan, G.A.R.Y., Abu-Odeh, A.M., Shehadeh, M.B., Shahwan, M., Jbara, F.A.
    • Year: 2022
    • Journal: PLoS ONE, Volume 17, Issue 12, Article e0278243